Clinical Trial Detail

NCT ID NCT02503358
Title Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors OHSU Knight Cancer Institute
Indications

lung adenocarcinoma

Therapies

Paclitaxel + Selumetinib

Age Groups: adult senior

No variant requirements are available.